Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Gains from Investment Securities (2021 - 2025)

Senti Biosciences' quarterly Gains from Investment Securities came in at $1.6 million in Q2 2025, up 0.82% year-on-year from $1.6 million in Q2 2024, and down 15.39% quarter-over-quarter from $1.9 million in Q1 2025.

Senti Biosciences has reported Gains from Investment Securities for 5 years, with the latest figure at $1.6 million in Q2 2025.

  • For the quarter ending Q2 2025, Gains from Investment Securities rose 0.82% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.5 million (up 11.36% YoY), and the FY2024 full-year result was -$20000.0, up 90.34% from the prior year.
  • Gains from Investment Securities for Q2 2025 stood at $1.6 million, down from $1.9 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $1.9 million in Q1 2025, with the low at -$9.5 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is -$1.1 million, with a median of $61000.0 recorded in 2023.
  • Year-over-year, Gains from Investment Securities plunged 105222.22% in 2022 and jumped 4074.29% in 2024.
  • Tracing SNTI's Gains from Investment Securities over 5 years: stood at $9000.0 in 2021, then sank by 105222.22% to -$9.5 million in 2022, then surged by 88.31% to -$1.1 million in 2023, then jumped by 107.87% to $87000.0 in 2024, then jumped by 1739.08% to $1.6 million in 2025.
  • The last three Gains from Investment Securities figures came in at $1.6 million (Q2 2025), $1.9 million (Q1 2025), and $87000.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Senti Biosciences Holdings 22.25 Mn 22.25 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 1.60 Mn
Jun 30, 2025 1.60 Mn
Mar 31, 2025 1.89 Mn
Mar 31, 2025 1.89 Mn
Dec 31, 2024 87,000.00
Dec 31, 2024 87,000.00
Jun 30, 2024 1.59 Mn
Jun 30, 2024 1.59 Mn
Mar 31, 2024 1.46 Mn
Mar 31, 2024 1.46 Mn
Dec 31, 2023 -1.11 Mn
Dec 31, 2023 -1.11 Mn
Jun 30, 2023 -148,000.00
Jun 30, 2023 -148,000.00
Mar 31, 2023 35,000.00
Mar 31, 2023 35,000.00
Dec 31, 2022 -9.46 Mn
Dec 31, 2022 -9.46 Mn
Sep 30, 2022 99,000.00
Sep 30, 2022 99,000.00
Jun 30, 2022 -8.88 Mn
Jun 30, 2022 -8.88 Mn
Dec 31, 2021 9,000.00
Dec 31, 2021 9,000.00